Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.746 SEK | +5.75% | -1.12% | +26.97% |
May. 23 | Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy | CI |
May. 21 | Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024 |
Sales 2024 * | - | Sales 2025 * | 578M 54.82M | Capitalization | 872M 82.76M |
---|---|---|---|---|---|
Net income 2024 * | -294M -27.91M | Net income 2025 * | -98M -9.3M | EV / Sales 2024 * | - |
Net Debt 2024 * | 56.6M 5.37M | Net Debt 2025 * | 657M 62.35M | EV / Sales 2025 * | 2.65 x |
P/E ratio 2024 * |
-2.08
x | P/E ratio 2025 * |
-2.4
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.23% |
Latest transcript on Cantargia AB
1 day | +5.75% | ||
1 week | -1.12% | ||
Current month | -1.12% | ||
1 month | +31.47% | ||
3 months | +71.46% | ||
6 months | +21.75% | ||
Current year | +26.97% |
Managers | Title | Age | Since |
---|---|---|---|
Göran Forsberg
CEO | Chief Executive Officer | 61 | 14-07-08 |
Patrik Renblad
DFI | Director of Finance/CFO | 54 | 23-06-14 |
David Liberg
CTO | Chief Tech/Sci/R&D Officer | 55 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Magnus Nilsson
BRD | Director/Board Member | 68 | 21-05-25 |
Chairman | 64 | 15-12-31 | |
Damian Marron
BRD | Director/Board Member | 62 | 21-05-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 4.746 | +5.75% | 299,959 |
24-06-05 | 4.488 | -6.11% | 314,927 |
24-06-04 | 4.78 | -4.40% | 586,387 |
24-06-03 | 5 | +4.17% | 1,045,917 |
24-05-31 | 4.8 | +11.84% | 1,642,315 |
Delayed Quote Nasdaq Stockholm, June 07, 2024 at 11:29 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.97% | 79.22M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.44% | 13.39B | |
+27.89% | 11.1B |
- Stock Market
- Equities
- CANTA Stock